Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

ClinicalTrials.gov ID: NCT00138216

Public ClinicalTrials.gov record NCT00138216. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors

Study identification

NCT ID: NCT00138216
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Children's Oncology Group; Network
Enrollment: 42 participants

Conditions and interventions

Conditions

Interventions

irinotecan hydrochloride Drug
temozolomide Drug
vincristine sulfate Drug

Drug

Eligibility (public fields only)

Age range: 1 Year to 21 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2005
Primary completion: May 31, 2009
Completion: Dec 31, 2010
Last update posted: Oct 1, 2023

2005 – 2011

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham	Birmingham	Alabama	35294	—
Children's Hospital of Orange County	Orange	California	92868	—
Stanford Cancer Center	Stanford	California	94305-5824	—
Children's Memorial Hospital - Chicago	Chicago	Illinois	60614	—
Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	46202-5289	—
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota	55455	—
Mayo Clinic Cancer Center	Rochester	Minnesota	55905	—
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center	New York	New York	10032	—
SUNY Upstate Medical University Hospital	Syracuse	New York	13210	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229-3039	—
Oregon Health and Science University Cancer Institute	Portland	Oregon	97239-3098	—
Lehigh Valley Hospital - Muhlenberg	Bethlehem	Pennsylvania	18107	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104-9786	—
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas	Dallas	Texas	75390	—
Children's Hospital and Regional Medical Center - Seattle	Seattle	Washington	98105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00138216, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 1, 2023 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00138216 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →